Quantitative muscle MRI combined with AI ‐based segmentation as a follow‐up biomarker for ATTRv patients: A longitudinal pilot study
European Journal of Neurology · 2025
DOI: 10.1111/ene.16574 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift European Journal of Neurology, 2025. Verfasst von Etienne Fortanier und 8 weiteren Autor:innen. Beteiligte Einrichtung: Reference Center for Neuromuscular Diseases and ALS, La Timone University Hospital, Aix-Marseille University, Marseille, France. Hauptthemen laut MEDLINE: Magnetic Resonance Imaging, Muscle, Skeletal, Amyloid Neuropathies, Familial. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background and Objectives Intramuscular fat fraction (FF), assessed using quantitative MRI (qMRI), has emerged as a promising biomarker for hereditary transthyretin amyloidosis (ATTRv) patients. Currently, the main drawbacks to its use in future therapeutic trials are its sensitivity to change over a short period of time and the time‐consuming manual segmentation step to extract quantitative data. This pilot study aimed to demonstrate the suitability of an Artificial Intelligence‐based (AI) segmentation technique to assess disease progression in a real‐life cohort of ATTRv patients over 1 year.
Methods
Fifteen ATTRv patients were included in this monocentric, observational, prospective study. FF, magnetization transfer ratio (MTR), and quantitative T2 were extracted from patients' lower limb qMRI at two time points, 1 year apart, at thigh and leg levels. qMRI parameters were correlated with clinical and electrophysiological parameters assessed at the same time.
Results
Global FF at leg level significantly progressed over 1 year: +1.28 ± 2.62% ( p = 0.017). At thigh level, no significant change in global FF, MTR, or T2 was measured. The leg FF was strongly correlated with the main clinical and electrophysiological scores.
Conclusion
AI‐based CNN network segmentation combined with qMRI can be used to obtain quantitative metrics for longitudinal studies in ATTRv patients. Global FF at the leg level seems to be the most sensitive MRI biomarker to track disease progression in a 1‐year period. Larger studies with treatment‐specific groups will now be necessary to determine the place of qMRI markers compared to the current clinical and electrophysiological scores.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Reference Center for Neuromuscular Diseases and ALS, La Timone University Hospital, Aix-Marseille University, Marseille, France.
- Center for Magnetic Resonance in Biology and Medicine, Aix-Marseille University, UMR CNRS 7339, Marseille, France.
- Aix Marseille University, CNRS, LIS, Marseille, France.
- Medicine Faculty, Aix-Marseille University, UMR 7286, Marseille, France.
- Aix-Marseille University, Inserm, GMGF, Marseille, France.
ORCID-Profile: Emilien Delmont, Annie Verschueren, David Bendahan
Zitieren
APA
Fortanier, E., Michel, C. P., Hostin, M. A., Delmont, E., Verschueren, A., Guye, M., Bellemare, M. E., Bendahan, D., & Attarian, S. (2025). Quantitative muscle MRI combined with AI ‐based segmentation as a follow‐up biomarker for ATTRv patients: A longitudinal pilot study. European Journal of Neurology. https://doi.org/10.1111/ene.16574
Vancouver
Fortanier E, Michel CP, Hostin MA, Delmont E, Verschueren A, Guye M, et al. Quantitative muscle MRI combined with AI ‐based segmentation as a follow‐up biomarker for ATTRv patients: A longitudinal pilot study. European Journal of Neurology. 2025. doi:10.1111/ene.16574
BibTeX
@article{Fortanier2025,
author = {Fortanier, Etienne and Michel, Constance P and Hostin, Marc Adrien and Delmont, Emilien and Verschueren, Annie and Guye, Maxime and Bellemare, Marc-Emmanuel and Bendahan, David and Attarian, Shahram},
title = {Quantitative muscle MRI combined with AI ‐based segmentation as a follow‐up biomarker for ATTRv patients: A longitudinal pilot study},
journal = {European Journal of Neurology},
year = {2025},
doi = {10.1111/ene.16574}
}
EUVIMED